Lansoprazole

• CAT Number: A000492
• CAS Number: 103577-45-3
• Molecular Formula: C16H14F3N3O2S
• Molecular Weight: 369.4
• Purity: ≥95%
• Target: Proton Pump
• Solubility: >18.5mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
• InChIKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N
• SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole which inhibits the stomach/’s production of gastric acids. As of 2015, laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer/’s disease. Lansoprazole is also a prodrug that targets the cytochrome bc1 complex of Mycobacterium tuberculosis once converted to lansoprazole sulfide in mycobacterial host cells.

Reference

1: Duwicquet F, Gras-Champel V, Masmoudi K. [Hyperprolactinemia with galactorrhea
induced by lansoprazole: A case report]. Therapie. 2017 Dec;72(6):691-693. doi:
10.1016/j.therap.2017.06.002. Epub 2017 Jul 26. French. PubMed PMID: 29061292.

2: Mizoguchi A, Higashiyama M, Ikeyama K, Nishii S, Terada H, Furuhashi H, Takajo
T, Maruta K, Yasutake Y, Shirakabe K, Watanabe C, Tomita K, Komoto S, Nagao S,
Miura S, Hokari R. Evaluation by MR Enterocolonography of Lansoprazole-induced
Collagenous Colitis Accompanied with Protein-losing Enteropathy – A Case Report.
Intern Med. 2017 Oct 16. doi: 10.2169/internalmedicine.8993-17. [Epub ahead of
print] PubMed PMID: 29033425.

3: Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K.
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised,
lansoprazole-controlled non-inferiority and single-blind extension study. Gut.
2017 Oct 7. pii: gutjnl-2017-314010. doi: 10.1136/gutjnl-2017-314010. [Epub ahead
of print] PubMed PMID: 28988197.

4: Chung HK, Truong QK, Mai XL, Choi Y, Kang JS, Mar W, Kim KH. Determination of
S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone
electrophoresis. Arch Pharm Res. 2017 Aug 1. doi: 10.1007/s12272-017-0936-8.
[Epub ahead of print] PubMed PMID: 28766240.

5: Mdanda S, Baijnath S, Shobo A, Singh SD, Maguire GEM, Kruger HG, Arvidsson PI,
Naicker T, Govender T. Lansoprazole-sulfide, pharmacokinetics of this promising
anti-tuberculous agent. Biomed Chromatogr. 2017 Jun 17. doi: 10.1002/bmc.4035.
[Epub ahead of print] PubMed PMID: 28623874.

6: Li X, Guo T, Lachmanski L, Manoli F, Menendez-Miranda M, Manet I, Guo Z, Wu L,
Zhang J, Gref R. Cyclodextrin-based metal-organic frameworks particles as
efficient carriers for lansoprazole: Study of morphology and chemical composition
of individual particles. Int J Pharm. 2017 Oct 15;531(2):424-432. doi:
10.1016/j.ijpharm.2017.05.056. Epub 2017 May 26. PubMed PMID: 28554546.

7: Shankar G, Borkar RM, Suresh U, Guntuku L, Naidu VGM, Nagesh N, Srinivas R.
Forced degradation studies of lansoprazole using LC-ESI HRMS and (1) H-NMR
experiments: in vitro toxicity evaluation of major degradation products. J Mass
Spectrom. 2017 Jul;52(7):459-471. doi: 10.1002/jms.3949. PubMed PMID: 28544042.

8: Aktas AH, Saridag AM. Liquid Chromatographic-Chemometric Techniques for the
Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin
in Commercial Preparation. J Chromatogr Sci. 2017 Sep 1;55(8):798-804. doi:
10.1093/chromsci/bmx039. PubMed PMID: 28449104.

9: Khaleel SA, Alzokaky AA, Raslan NA, Alwakeel AI, Abd El-Aziz HG, Abd-Allah AR.
Lansoprazole halts contrast induced nephropathy through activation of Nrf2
pathway in rats. Chem Biol Interact. 2017 May 25;270:33-40. doi:
10.1016/j.cbi.2017.04.010. Epub 2017 Apr 13. PubMed PMID: 28412091.

10: Lorberbaum T, Tatonetti NP. Reply: Combination Therapy With Ceftriaxone and
Lansoprazole, Acquired Long QT Syndrome and Torsades de Pointes Risk. J Am Coll
Cardiol. 2017 Apr 11;69(14):1877-1878. doi: 10.1016/j.jacc.2016.12.042. PubMed
PMID: 28385320.